Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04927793 · ClinicalTrials.gov registry record · Phase 1
Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects
A Phase 1 study, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04927793 is a Phase 1 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT04927793, a Phase 1 study, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
A Phase 1, Open-label Study of the absorption, metabolism, and excretion of a single oral dose of \[14C\]EDP-938 in healthy male subjects.
Interventions
- DRUG EDP-938
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-05-28 |
| Est. Completion | 2021-07-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04927793
The ClinicalTrials.gov registry entry for NCT04927793 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EDP-938 is the first listed.
NCT04927793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04927793 about?
NCT04927793 is a clinical study titled "Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects". A Phase 1, Open-label Study of the absorption, metabolism, and excretion of a single oral dose of \[14C\]EDP-938 in healthy male subjects.
What is the current status of trial NCT04927793?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-05-28. Estimated completion is 2021-07-04.
What interventions are being tested in trial NCT04927793?
The interventions under investigation include: EDP-938 (DRUG).
Who is sponsoring clinical trial NCT04927793?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.